Protagen AG Appoints Bernhard Kirschbaum as New Board Member

DORTMUND, Germany--()--PROTAGEN AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics (CDx) in the autoimmune field, today announced that the former Head of Research and Early Development of Merck Serono, Dr. Bernhard Kirschbaum, has joined the company’s Supervisory Board.

This news follows the recently announced strategic partnership between Protagen and QIAGEN, which will focus on pharma collaborations in the autoimmune space, an area where Dr. Kirschbaum has significant expertise.

Dr. Kirschbaum has served in executive positions at Hoechst, Aventis, Sanofi, and Merck Serono, and has a proven track record in preclinical and clinical R&D, with a special focus on autoimmune diseases and chronic inflammatory disorders. According to Dr. Kirschbaum, “Protagen offers a very solid, unique technology with broad application potential. It is of particular relevance for translational research, which remains a central topic in drug development. In many diseases, analyses at the protein level offer key insights and guidance on diseases status and drug development.”

Stefan Müllner, CEO of Protagen, added: “In order to become the leading provider of CDx for autoimmune therapy, it is imperative that we have meaningful insight into the R&D processes and interfaces of big pharma. The profound expertise Dr. Kirschbaum will bring to this role will provide us with valuable guidance, which will enable us to effectively expand our business within the growing CDx field.”

About Protagen – Diagnostics Differentiated

Protagen AG, headquartered in Dortmund, Germany, specializes in the development of novel diagnostic and companion diagnostic tests to provide better and earlier diagnosis of autoimmune diseases.

Protagen uses its proprietary SeroTag biomarker platform to identify disease specific autoantibodies and is on target to become the leading provider of autoimmune diagnostic products, specifically targeting diseases with an unmet need for effective diagnostics.

With pioneering bioscience techniques, extensive scientific expertise and a broad patent portfolio, Protagen works to develop its own diagnostic pipeline and partners with other organizations to develop and implement new companion diagnostic tools for better personalized treatment strategies.

For more information, please visit www.protagen.com

Contacts

Protagen AG
Dr. Stefan Müllner
CEO
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: bd@protagen.com
or
Media Enquiries
BioStrata
Dr. Clare Russell
Managing Director
Tel: +44 1223 828200
Mob: +44 7812 343412
E-Mail: crussell@biostratamarketing.com

Release Summary

PROTAGEN, specialist in the development of diagnostic tests and companion diagnostics in the autoimmune field, today announced that Dr. Bernhard Kirschbaum has joined the company’s Supervisory Board.

Contacts

Protagen AG
Dr. Stefan Müllner
CEO
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: bd@protagen.com
or
Media Enquiries
BioStrata
Dr. Clare Russell
Managing Director
Tel: +44 1223 828200
Mob: +44 7812 343412
E-Mail: crussell@biostratamarketing.com